Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| I mean we had very strong data in the last study we did, so we're pretty excited about it |
| Today, we announced a strong step in the right direction with a greater than 60% increase in revenue this quarter versus last quarter |
| We're very excited about it |
| So, once they're taken care of and we can focus our efforts 100% on new customers, that will be very exciting for us as a team |
| I don't think that was a big deal, but certainly, nicer for the hospitals to have that, and we're able to improve on the alarms |
| We think that the data that have been generated are very strong |
| For reference, upgrading our software removes all compatibility issues, reduces the system noise, improves alarms and improves sensor accuracy |
| While still in its early stages, we have also been pleased with the progress made since securing our innovative technology contract award from Vizient, the nation's largest provider-driven healthcare performance improvement company |
| Everybody is very pleased and happy with it |
| We're very happy to do so |
| So, I'm very happy to hear that they may be able to help patients, that's fantastic |
| Nitric oxide enhances the efficacy and certainly helps with the tolerability of antibiotics as we've seen in our studies |
| We're excited by this opportunity to expand our reach through the Vizient customer network |
| I wish Duncan the best and he's done a great job for us |
| We are pleased that the program remains on track for human data in 2025 |
| So, I think it's a good thing |
| Like we mentioned in some of the prepared remarks, seeing customers asking for longer-term contracts with us, locking us in, which is very good |
| So, at this point, any success with antibiotics is great for us, great for patients |
| I think it's a healthy pricing environment |
| So, I think they are all positive |
| Our clinical and regulatory team is to be commended for putting together a strong submission |
| But we have a pretty strong team here internally |
| That's good |
| They're doing pretty good volume, even the two ones that I would consider to be a little bit below what the average-sized hospital would be, do pretty good volume |
| To capitalize on this positive growth trajectory, we will continue to build out a field team based on the growth opportunities as they evolve |
| We do feel confident in our application |
| We believe this program offers tremendous potential and look forward to providing updates as we progress throughout the year |
| Please recall that this early stage development program is being conducted in partnership with The Hebrew University of Jerusalem, which continued to produce exciting preclinical data |
| Filters shipped in fiscal 3Q grew by more than 100% compared with shipments in fiscal 2Q |
| The increase in demand for product evaluations has surged since our upgraded system was displayed at the American Academy of Respiratory Care in early November |
| Statement |
|---|
| While we are seeing positive operating margins on our individual contracts, there are three reasons why our overall gross margin remains negative |
| So, there's a lot of things that three-and-a-half years of this -- of no changes in our system where the rest of the world is having changes makes it difficult for us to catch up right away |
| Third, consistent with this early stage of growth, we are suboptimal in our physical warehousing infrastructure, but as we grow this effect will dissipate |
| As this rollout of the new machines has just begun, the financial impact in the March quarter will be a bit muted as compared with the levels of revenue we expect to see in the June quarter |
| And a little frustrating that it took as long as it did, but it's here now, and the feedback is as expected |
| Steve Lisi So, it was stopped for negative reasons? Yale Jen For negative reasons |
| For the fiscal quarter ended December 31, 2023, on a GAAP basis, the company recorded a net loss of $17.1 million, of which $16.1 million or $0.50 per share was attributable to the shareholders of Beyond Air, Inc |
| And right now, it's a pure guess on my part because the interactions with FDA, as you're aware, we're still a little bit short of when you would normally hear feedback from FDA |
| Again, as long as it doesn't push out our pivotal study start, I don't think it's a problem at all |
| compared with a net loss of $12.7 million or $0.43 a share for the fiscal quarter ended December 31, 2022 |
| Beyond Air cautions that these forward-looking statements are subject to risks and uncertainties, could cause actual results to differ materially from those indicated |
| And then, in terms of the PMA supplement for cardiac surgery, obviously, the label and approval took a lot longer than you expected for initial indication |
| This is not how it works |
| And I think that -- I've said this before, I think that the pricing environment is not too far off from what we expected when we entered this market |
| I mean it's very difficult to pinpoint it |
| I mean you can't be sure, but that's a rough estimate, and then we'll have to ramp things up |
| Second, because we prebuilt several hundred devices that are currently being upgraded, we have depreciation of devices that are not currently generating revenue |
| So, I wouldn't think it would be very impactful |
| There's no doubt about it |
| Bronchiolitis also on hold |
Please consider a small donation if you think this website provides you with relevant information